Status:
TERMINATED
Safety and Efficacy of TAK-559 in Combination With Metformin in Patients With Type 2 Diabetes Mellitus.
Lead Sponsor:
Takeda
Conditions:
Diabetes Mellitus
Eligibility:
All Genders
25-75 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to evaluate the safety and efficacy of TAK-559, once daily (QD), taken in combination with metformin in treating subjects with type 2 diabetes mellitus
Detailed Description
Insulin is a primary regulator of blood glucose concentrations. A subnormal response to circulating insulin levels at target tissues leads to a decrease in insulin-mediated glucose uptake. Insulin res...
Eligibility Criteria
Inclusion
- Diagnosed with type 2 diabetes mellitus, and on a stable dose of an oral antidiabetic monotherapy before Screening A.
- Female patients of childbearing potential who were sexually active agreed to use adequate contraception, and could neither pregnant nor lactating from Screening throughout the duration of the study.
- Had a glycosylated hemoglobin level greater than or equal to 8.0% and less than or equal to 10.0% at Screening B.
- Had a fasting plasma glucose greater than or equal to 126 mg/dL (7.0 mmol/L) at Screening B.
- Taking a stable dose of at least 1000 mg of metformin for at least 30 days before Screening B.
- Had a stable or worsening self-monitoring blood glucose level while taking metformin.
- Had a low-density lipoprotein less than 160 mg/dL (4.1 mmol/L) at Screening A.
- Had a body mass index was less than or equal to 45 kg/m2 at Screening A.
- Was willing to be counseled by the investigator or designee to follow an individualized, weight-maintaining diet during the study period.
- Had evidence of insulin secretory capacity as demonstrated by a C-peptide concentration of greater than or equal to 1.5 ng/mL (0.50 nmol/L) at Screening A, and if necessary, after a repeat at Screening B.
- Was able to perform daily self-monitoring blood glucose tests throughout the study.
- Had a normal thyroid-stimulating hormone level of less than 5.5 μIU/mL (5.5 mIU/L) and greater than or equal to 0.35 μIU/mL (0.35 mIU/L) at Screening A.
- Was in good health as determined by a physician (ie, via medical history and physical examination), other than a diagnosis of type 2 diabetes mellitus.
- Had fasting clinical laboratory results within the normal ranges for the testing laboratory, or if not, the results were deemed not clinically significant by the investigator before Randomization.
Exclusion
- Diagnosed with type 1 diabetes mellitus, hemochromatosis, or had a history of ketoacidosis.
- Had any condition known to invalidate glycosylated hemoglobin results (eg, hemolytic states or hemoglobinopathies).
- Took any disallowed medication, prescription medication, herbal treatment or over-the counter medication that may have interfered with evaluation of the study medication, including:
- Insulin
- Oral antidiabetics including sulfonylureas and alpha-glucosidase inhibitors
- Systemic corticosteroids
- Warfarin
- Rifampin
- St. John's Wort.
- Thiazolidinediones
- Peroxisome proliferator-activated receptor agonists
- Nicotinic Acid
- Fibrates
- Had a history of myocardial infarction, coronary angioplasty or bypass graft, unstable angina pectoris, transient ischemic attacks, clinically significant abnormal electrocardiogram, or documented cerebrovascular accident within 6 months before Screening A.
- Had abdominal, thoracic, or vascular surgery within 6 months before Screening A that in the investigator's opinion warranted exclusion from the study.
- Had a creatine phosphokinase value greater than 3 times the upper limit of normal at Screening A.
- Had persistent unexplained microscopic or macroscopic hematuria or a history of bladder cancer.
- Had a triglyceride level greater than 500 mg/dL (5.6 mmol/L) at Screening A.
- Received any alteration in allowed lipid lowering medication (dose or drug) within 2 months of Randomization, if applicable. The patient remained on a stable dose throughout the study. If deemed necessary, the dose could have been lowered with prior approval from the Sponsor.
- Donated and/or received any blood or blood products within 3 months before Randomization.
- Had a history of drug abuse or a history of alcohol abuse within 2 years before Randomization
- Had a systolic blood pressure greater than 140 mm Hg or a diastolic blood pressure of greater than 95 mm Hg at Screening B.
- Had significant cardiovascular disease including but not limited to, New York Heart Association Functional (Cardiac) Classification III or IV.
- Had a history of cancer other than basal cell or stage 1 squamous cell carcinoma of the skin that had not been in remission within 5 years before Randomization.
- Had an alanine aminotransferase or aspartate aminotransferase level greater than 3 times the upper limit of normal, active liver disease, or jaundice at Screening A.
- Had a positive anti-hepatitis B surface antigen, or anti-hepatitis B e antigen test results at Screening A.
- Was currently taking another investigational study medication or had taken an investigational study medication within 30 days before Screening A.
- Had any other serious disease or condition at Screening A or at Randomization that might have affected life expectancy or made it difficult to successfully manage and follow the patient according to the protocol.
Key Trial Info
Start Date :
November 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2004
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT00762957
Start Date
November 1 2004
End Date
December 1 2004
Last Update
February 28 2012
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.